Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T74483
|
||||
| Former ID |
TTDR00544
|
||||
| Target Name |
Potassium voltage-gated channel subfamily KQT member 2
|
||||
| Gene Name |
KCNQ2
|
||||
| Synonyms |
K+ channel KCNQ2; KQT-like 2; Neuroblastoma-specific potassium channel KQT-like 2; Neuroblastoma-specific potassium channel alpha subunit KvLQT2; Voltage-gated potassium channel subunit Kv7.2; KCNQ2
|
||||
| Target Type |
Research
|
||||
| Disease | Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89] | ||||
| Function |
Probably importantin the regulation of neuronal excitability. Associates with kcnq3 to form a potassium channel with essentially identical properties to the channel underlying the native m-current.
|
||||
| BioChemical Class |
Voltage-gated ion channel
|
||||
| UniProt ID | |||||
| Sequence |
MVQKSRNGGVYPGPSGEKKLKVGFVGLDPGAPDSTRDGALLIAGSEAPKRGSILSKPRAG
GAGAGKPPKRNAFYRKLQNFLYNVLERPRGWAFIYHAYVFLLVFSCLVLSVFSTIKEYEK SSEGALYILEIVTIVVFGVEYFVRIWAAGCCCRYRGWRGRLKFARKPFCVIDIMVLIASI AVLAAGSQGNVFATSALRSLRFLQILRMIRMDRRGGTWKLLGSVVYAHSKELVTAWYIGF LCLILASFLVYLAEKGENDHFDTYADALWWGLITLTTIGYGDKYPQTWNGRLLAATFTLI GVSFFALPAGILGSGFALKVQEQHRQKHFEKRRNPAAGLIQSAWRFYATNLSRTDLHSTW QYYERTVTVPMYSSQTQTYGASRLIPPLNQLELLRNLKSKSGLAFRKDPPPEPSPSKGSP CRGPLCGCCPGRSSQKVSLKDRVFSSPRGVAAKGKGSPQAQTVRRSPSADQSLEDSPSKV PKSWSFGDRSRARQAFRIKGAASRQNSEEASLPGEDIVDDKSCPCEFVTEDLTPGLKVSI RAVCVMRFLVSKRKFKESLRPYDVMDVIEQYSAGHLDMLSRIKSLQSRVDQIVGRGPAIT DKDRTKGPAEAELPEDPSMMGRLGKVEKQVLSMEKKLDFLVNIYMQRMGIPPTETEAYFG AKEPEPAPPYHSPEDSREHVDRHGCIVKIVRSSSSTGQKNFSAPPAAPPVQCPPSTSWQP QSHPRQGHGTSPVGDHGSLVRIPPPPAHERSLSAYGGGNRASMEFLRQEDTPGCRPPEGN LRDSDTSISIPSVDHEELERSFSGFSISQSKENLDALNSCYAAVAPCAKVRPYIAEGESD TDSDLCTPCGPPPRSATGEGPFGDVGWAGPRK |
||||
| Drugs and Mode of Action | |||||
| Activator | (S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide | Drug Info | [528363] | ||
| ICA-27243 | Drug Info | [530361] | |||
| PIP2 | Drug Info | [527827] | |||
| QO-58 | Drug Info | [532057] | |||
| zinc pyrithione | Drug Info | [528790] | |||
| ztz240 | Drug Info | [530996] | |||
| Modulator | ICA-69673 | Drug Info | |||
| Inhibitor | PD-32577 | Drug Info | [525576] | ||
| Blocker (channel blocker) | tetraethylammonium | Drug Info | [525854] | ||
| XE991 | Drug Info | [534766] | |||
| Pathways | |||||
| KEGG Pathway | Cholinergic synapse | ||||
| PANTHER Pathway | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | ||||
| Reactome | Voltage gated Potassium channels | ||||
| Interaction between L1 and Ankyrins | |||||
| WikiPathways | Potassium Channels | ||||
| L1CAM interactions | |||||
| References | |||||
| Ref 525576 | Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. | ||||
| Ref 525854 | Mol Pharmacol. 2000 Sep;58(3):591-600.Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. | ||||
| Ref 527827 | Regulation of Kv7 (KCNQ) K+ channel open probability by phosphatidylinositol 4,5-bisphosphate. J Neurosci. 2005 Oct 26;25(43):9825-35. | ||||
| Ref 528363 | The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology. 2006 Nov;51(6):1068-77. Epub 2006 Aug 10. | ||||
| Ref 528790 | Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007 May;3(5):287-96. Epub 2007 Apr 15. | ||||
| Ref 530361 | The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site. Neurosci Lett. 2009 Nov 13;465(2):138-42. | ||||
| Ref 530996 | Isoform-specific prolongation of Kv7 (KCNQ) potassium channel opening mediated by new molecular determinants for drug-channel interactions. J Biol Chem. 2010 Sep 3;285(36):28322-32. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.